Research and Markets: Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirf

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/773815/respiratory_disord) has announced the addition of the "Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries" report to their offering.

Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries provides insights into the global respiratory disorders market and market forecast until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The report provides in-depth analysis of the major respiratory disorders. The report provides an in-depth analysis of the top seven respiratory disorders indications, which include asthma, COPD, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, allergic rhinitis, cystic fibrosis and bronchitis. The report examines the global respiratory disorders treatment usage patterns the US, the top five European countries and Japan. The report also includes insights into the respiratory disorders R&D product pipeline and explores the competitive landscape including major players in respiratory disorders market. Finally, the report includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in the respiratory disorders market.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Patent Expiries and Generic Competition Are Negatively Impacting upon the Market, Reducing its CAGR from 7.7% in 2002-2010 to 3.1% in 2010-2017 Companies Mentioned:

  • AstraZeneca
  • GlaxoSmithKline
  • Merck & Co., Inc.
  • Actelion
  • Novartis

For more information visit http://www.researchandmarkets.com/research/773815/respiratory_disord



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.